Latest
Sources
Trade Ideas
Speakers
Sign in
Go
Johnson & Johnson Announce Breakthrough Therapy Designation From FDA For RYBREVANT In Non-Small Cell Lung Cancer
Original source ↗
| February 18, 2026 at 08:36 UTC |
Finnhub - JNJ
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
JNJ
NONE
Finnhub News
—
—